LIFECORE BIOMEDICAL INC (LFCR) Stock Analyst Ratings
NASDAQ:LFCR - Nasdaq - US5147661046 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 80% to LFCR. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.2. This target is 51.79% above the current price.
LFCR was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about LFCR.
In the previous month the buy percentage consensus was at a similar level.
LFCR was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-05-21 | William Blair | Initiate | Outperform |
| 2025-01-03 | Stephens & Co. | Reiterate | Equal-Weight -> Equal-Weight |
| 2024-11-22 | Craig-Hallum | Maintains | Buy -> Buy |
| 2024-09-05 | Craig-Hallum | Initiate | Buy |
| 2024-08-28 | Barrington Research | Downgrade | Outperform -> Market Perform |
| 2023-09-01 | Barrington Research | Maintains | Outperform -> Outperform |
| 2023-09-01 | Stephens & Co. | Maintains | Equal-Weight -> Equal-Weight |
| 2023-06-02 | Barrington Research | Maintains | Outperform -> Outperform |
| 2023-05-24 | Barrington Research | Maintains | Outperform -> Outperform |
| 2023-03-21 | Barrington Research | Maintains | Outperform |
| 2023-03-20 | Barrington Research | Maintains | Outperform |
| 2023-03-20 | Stephens & Co. | Downgrade | Overweight -> Equal-Weight |
| 2023-03-17 | Stephens & Co. | Reiterate | Overweight |